...
首页> 外文期刊>Medizinische Klinik >Pharmacological treatment of COPD and future of anti-inflammatory therapy
【24h】

Pharmacological treatment of COPD and future of anti-inflammatory therapy

机译:COPD的药理学治疗和抗炎治疗的未来

获取原文
获取原文并翻译 | 示例
           

摘要

Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. It is caused by chronic inflammation of the airways and the lung parenchyma. Symptomatic treatment is based on bronchodilatation, which leads to a reduction of hyperinflation and relief of dyspnea. Smoking cessation is the only known causative treatment option. Inhaled corticosteroids (ICS) reduce exacerbations and, potentially, mortality. Future therapies should ameliorate chronic inflammation and thus stop the annual decline of lung function. In face of increasing mortality and morbidity more research is needed.
机译:慢性阻塞性肺疾病(COPD)的特征是不能完全逆转的气流受限。它是由气道和肺实质的慢性炎症引起的。对症治疗基于支气管扩张,可减轻过度通气并缓解呼吸困难。戒烟是唯一已知的因果疗法。吸入皮质类固醇(ICS)可以减轻病情加重,并有可能降低死亡率。未来的疗法应可减轻慢性炎症,从而停止每年的肺功能下降。面对不断增加的死亡率和发病率,需要进行更多的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号